Pioglitazone Bioton — Sugar control and insulin sensitivity
Trade Name: Pioglar (Pioglitazone Bioton)
Release form: Tablets
Dosage: 45 mg
About the product
Pioglar is a modern drug for adults with type 2 diabetes mellitus. It is designed for those cases when diet and physical activity are no longer sufficient to maintain normal blood glucose levels.
Unlike many other drugs, Pioglar does not just "reduce sugar" — it affects the root of the problem: it increases the natural sensitivity of cells to insulin. Due to this, the body begins to use its own insulin more efficiently, insulin resistance (tissue insensitivity) decreases, and glucose levels return to normal.
Key action:
Increases the sensitivity of muscles, liver and adipose tissue to insulin.
Improves glucose utilization by the body.
Provides stable glycemic control.
Composition
Active substance: Pioglitazone hydrochloride — 45 mg in one tablet.
The drug is used in adults with type 2 diabetes. The doctor may recommend it in the following treatment regimens:
Monotherapy — if metformin is not suitable or contraindicated.
Dual therapy — in combination with metformin or with sulfonylurea derivatives (SM), when one tablet has no effect.
Triple therapy — simultaneously with metformin and CM drugs with uncontrolled glucose levels.
Together with insulin, if insulin itself cannot cope, and metformin is contraindicated or poorly tolerated.
How to accept
The drug is taken orally, strictly as prescribed by a doctor. The dosage is selected individually. Important: do not change the dose yourself, even if it seems to you that the effect is insufficient.
When not to use (Contraindications)
Before buying, make sure that you do not have the following conditions (strictly prohibited):
Heart failure (any NYHA classes I–IV).
Liver function disorders.
Diabetic ketoacidosis.
Bladder cancer (present or past).
Blood in the urine (hematuria) of unknown origin.
Allergy to any component of the product.
Possible side effects
Like any serious drug, Pioglar can cause reactions. The most common cases (no more than 1 in 10 patients) are:
Respiratory infections.
Mild visual impairment.
Weight gain.
Numbness of the extremities.
A more complete list is described in the official instructions.
Important warnings (before admission)
Be sure to tell your doctor if you have:
Fluid retention in the body (edema).
Eye diseases (especially macular edema).
Polycystic ovary syndrome (PCOS) — in women (the drug can unexpectedly restore ovulation and increase the risk of pregnancy).
Anemia.
Planning a pregnancy.
Special instructions:
Fractures: In women, the risk of fractures is higher (especially in the extremities). The doctor will take this into account when choosing therapy.
Hypoglycemia: Possible in combination with other hypoglycemic agents.
Edema: The drug can cause fluid retention, which is dangerous in heart failure (especially in the elderly and when taking anti-inflammatory drugs).
Effectiveness: If there is no expected result after 3-6 months of treatment, the therapy is canceled.
Interactions with other medications
Warn your doctor if you are taking:
Gemfibrozil (for lowering cholesterol).
Rifampicin (an antibiotic for the treatment of tuberculosis and infections).
Pregnancy, lactation, and age
Pregnancy and GW: Use is not recommended and is prohibited during breast-feeding.
Children and adolescents under 18 years of age: Not used (no safety data available).
Driving a car: Be careful if you have visual impairments during the reception.
Manufacturer
BIOTON
Macierzysz, ul. Poznańska 12
05-850 Ożarów Mazowiecki Poland